2150P - Clinical and molecular characterisation of cancer-associated venous thromboembolism (VTE)

Background

VTE is a major, preventable complication in cancer patients (pts) and the second cause of mortality. Our aim is to describe clinical and pathological features of cancer pts with VTE and compare them to pts without VTE.

Methods

A retrospective case-control study of cancer pts with VTE diagnosed in 2022 at Vall Hebron Hospital (cases) and cancer pts without VTE treated at same centre (controls) was conducted. Clinical features including cancer site, stage, pathological/molecular profile, and therapy were registered; univariate analysis was performed.

Results

85 cases and 100 controls were analysed. Cases characteristics: 53% females, mean age 61. Most common cancers shown in the table. Cancer was locally advanced/metastatic in 78.8%. According to Khorana score, 75.3% had intermediate/high risk for VTE. Most common histology in lung was adenocarcinoma (ADK) (72.7%); 14.3% EGFR mutated. In breast, 93.3% were invasive ductal carcinomas (IDC), 93.3% expressed hormone receptors (HR), 40% HER2 positive, 6.7% germline BRCA mutation. All CRC were ADKs, 40% RAS mutations and 13% microsatellite instability (MSI). 82.4% of pts received chemotherapy (CT), 16.5% immunotherapy (IO), 15.3% hormone therapy (HT), 12.9% antiangiogenics, 10.6% tyrosine kinase inhibitors. Comparative analysis (Table): female sex was associated with VTE (Odds Ratio [OR], 2; 95%CI, 1.1-3.6). As to cancer type, only breast was associated with VTE (OR, 2.6; 95%CI, 1.01-6.8). Conversely, head and neck cancers had negative association with VTE (OR, 0.2; 95%CI, 0.04-0.9). No differences were observed regarding cancer stage. CT (OR, 6.72; 95%CI, 3.4-13.3), HT (OR, 3.4; 95%CI, 1.2-10.1) and targeted therapies (OR, 3.06; 95%CI 1.43-6.56) were associated with VTE; IO was not. Table: 2150P

Characteristics of cases and controls

Conclusions

Most common cancers in pts with VTE were lung (14% EGFR mutated), breast (HR positive 93%; HER2 positive 40%) and CRC (40% RAS mutated). Female sex and breast cancer were associated to VTE. CT, HT and targeted therapies were all associated with VTE.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.